Prophylactic Dosing for Multiple Myeloma Patients
For patients with multiple myeloma, administer acyclovir 400 mg orally once daily for herpes virus prophylaxis and trimethoprim-sulfamethoxazole (Bactrim) DS one tablet daily for Pneumocystis prophylaxis throughout the duration of active myeloma treatment.
Acyclovir Prophylaxis
Dosing Recommendation
- Acyclovir 400 mg orally once daily is the established prophylactic dose 1, 2
- Continue throughout the entire duration of myeloma treatment, not just during specific therapy cycles 1
- No routine monitoring required while on prophylaxis 1
Evidence Base
The 2023 expert consensus on bispecific antibody therapy explicitly recommends acyclovir or valacyclovir against HSV and VZV in all relapsed/refractory multiple myeloma patients 1. The 2018 ASCO/IDSA guideline similarly recommends antiviral prophylaxis with nucleoside analogs (such as acyclovir) for HSV-seropositive patients undergoing leukemia induction therapy, continuing until WBC recovery or mucositis resolution 2.
Multiple retrospective studies confirm that acyclovir 400 mg once daily completely prevents VZV reactivation in myeloma patients receiving bortezomib-based therapies. One series of 100 patients showed zero herpes zoster cases with this regimen 3, while another study of 55 patients on the once-daily dose had no VZV reactivations compared to 36% in unprotected patients 4. A Korean study similarly found no herpes zoster in patients receiving 400 mg daily through their entire bortezomib treatment course 5.
Critical Pitfall
Do not use lower doses. Studies show that 200 mg daily is insufficient—all breakthrough infections occurred in patients receiving this reduced dose 5. The 400 mg once-daily regimen is both necessary and sufficient.
Trimethoprim-Sulfamethoxazole (Bactrim) Prophylaxis
Dosing Recommendation
- Bactrim DS (double strength) one tablet daily for Pneumocystis jirovecii prophylaxis 2, 6
- This provides 160 mg trimethoprim/800 mg sulfamethoxazole per day
- Continue throughout immunosuppressive therapy
Evidence Base
The 2018 ASCO/IDSA guideline recommends TMP-SMX prophylaxis for patients receiving chemotherapy regimens associated with >3.5% risk for Pneumocystis pneumonia, particularly those on ≥20 mg prednisone equivalents daily for ≥1 month 2. The FDA-approved prophylactic dose is one DS tablet daily 6.
Important Nuance on Bacterial Infection Prevention
TMP-SMX does NOT reduce early bacterial infections in newly diagnosed myeloma patients receiving standard induction chemotherapy. Two randomized trials showed no significant reduction in serious bacterial infections during the first 2 months of treatment 7, 8. The 2012 ECOG trial found comparable infection rates whether patients received ciprofloxacin, TMP-SMX, or observation (12.5% vs 6.8% vs 15.9%, P=0.218) 7.
However, an older 1996 trial did show benefit (2 vs 11 infections, P=0.004) 8, but this predates modern supportive care. The primary indication for TMP-SMX in myeloma is Pneumocystis prophylaxis, not routine bacterial infection prevention.
When to Use Fluoroquinolone Instead
For patients at high risk of febrile neutropenia or profound, protracted neutropenia, the ASCO/IDSA guideline recommends fluoroquinolone prophylaxis during the period of expected neutropenia 2. This is a separate indication from Pneumocystis prophylaxis.
Duration of Prophylaxis
Continue both agents throughout active myeloma treatment. The 2023 consensus specifically states prophylaxis should be maintained while the patient is receiving treatment for MM, with continuation thereafter at physician discretion 1. This is particularly critical for patients on:
- Bispecific antibodies (which cause profound, durable hypogammaglobulinemia)
- CAR-T cell therapy
- Proteasome inhibitors like bortezomib
- High-dose corticosteroids
Renal Dose Adjustment
For patients with impaired renal function on Bactrim 6:
- Creatinine clearance >30 mL/min: Standard dose
- Creatinine clearance 15-30 mL/min: Reduce to half the usual dose
- Creatinine clearance <15 mL/min: Use not recommended
Acyclovir also requires renal dose adjustment per FDA labeling, though the prophylactic 400 mg daily dose is generally well-tolerated 9.